Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-06-11

Ocular hypotensive and retinal neuroprotective activity of topical calcium channel blockers

Obiettivo



Research objectives and content
Nowadays, it is thought that the ideal antiglaucoma drug should not only lower intraocular pressure but also act as retinal neuroprotective agent either by improving ocular blood flow or, especially, by counteracting the mechanisms responsible for neuronal toxicity.
Among potential antiglaucoma drugs, topical calcium channel blockers may combine the characteristics being demanded for the ideal antiglaucoma drug. The topical application of L-type calcium channel blockers has been found to lower intraocular pressure both in rabbits and men. Nevertheless, it is unknown whether topical L-type calcium channel blockers can really act as retinal neuroprotective drugs, although a beneficial effect might be expected since retinal damage seems to be finally produced by extracelular calcium entry thorough voltage-gated calcium channels. Furthermore, it has not been yet examined whether other calcium channel blockers, such as those of the N-, P- and T-type, may also behave as ocular hypotensive and/or retinal neuroprotective drugs.
Therefore, this research project has the following main objectives: -To examine the potential retinal neuroprotective effect of topically applied L-type calcium channel blockers. -To examine whether N-, P- or T-type calcium channel blockers may also behave as ocular hypotensive and/or retinal neuroprotective drugs.
Training content (objective, benefit and expected impact)
By means of this, research project, the applicant aims to acquire the skills needed for studying the mechanism of retinal neurotoxicity and for the testing of potential neuroprotective drugs. If a retinal neuroprotective effect of topical calcium channel blockers were found in these studies, these drugs would be the first antiglucauma agents clearly showing both ocular hypotensive and retinal neuroprotective activity, a fact that may provide a prominent role for topical calcium channel blockers in antiglucauma therapy.
Links with industry / Industrial relevance (22)

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Invito a presentare proposte

Dati non disponibili

Meccanismo di finanziamento

RGI - Research grants (individual fellowships)

Coordinatore

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Contributo UE
Nessun dato
Indirizzo
Walton Street
OX2 6AW OXFORD
Regno Unito
Costo totale
Nessun dato